Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


About us

MEDtalks is an independent multidisciplinary Internet TV channel for medical professionals. Congress News, Discussion Rounds, Interviews with scientists, research results, and accredited refresher courses will be published on this website for registered healthcare professionals.


Login Register

Featured Articles

Congress news 10/07/2020

Discussion round on the WCGIC Highlights

In this discussion, 5 experts from Switzerland and Germany evaluate the impact of the most important findings from the WCGIC on their daily practice.   Egalement disponible en français. Veuillez cliquer ici.

Congress news 06/07/2020

Upper GI - Highlights WCGIC

In this presentation, Thomas Winder, Swiss Tumor Molecular Institute, Zurich covers the most important findings from the ESMO WCGIC for upper GI.   He selected the following studies and topics:   Adenocarcinoma O-10: Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010 David Ilson et al., Rhode Island, USA   O-11: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, openlabel study (DESTINY-Gastric01) Kensei Yamaguchi et al. O-12: KEYNOTE-061: response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma Harry H. Yoon et al., Rochester, MN, USA   Pancreatic Cancer LBA-1: First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Primary analysis from a phase 1/2 study Zev Wainberg et al., Los Angeles, CA, USA   PD-6: Gemcitabine + nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a population-based, multicenter AGEO study. Sonia Zaibet et al., Paris, France   Cholangiocarcinoma SO-5: Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis Milind Javle et al.   HCC O-8: Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150 Daneng Li, Duarte, CA, USA   GIST O-13: Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS César Serrano et al., Barcelona, Spain   return to overview

Congress news 08/07/2020

Gastro-intestinale supérieure - Résumé du WCGIC

Dans cette présentation, Thomas Winder, du Swiss Tumor Molecular Institute de Zurich, présente les principaux résultats de l'ESMO WCGIC pour le gastro-intestinale supérieure.   Il a sélectionné les études et les sujets suivants :   Adénocarcinoma O-10: Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010 David Ilson et al., Rhode Island, USA   O-11: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, openlabel study (DESTINY-Gastric01) Kensei Yamaguchi et al.   O-12: KEYNOTE-061: response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma Harry H. Yoon et al., Rochester, MN, USA   Cancer du pancréas LBA-1: First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Primary analysis from a phase 1/2 study Zev Wainberg et al., Los Angeles, CA, USA   PD-6: Gemcitabine + nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a population-based, multicenter AGEO study. Sonia Zaibet et al., Paris, France   Cholangiocarcinome SO-5: Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis Milind Javle et al.   HCC O-8: Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150 Daneng Li, Duarte, CA, USA   GIST O-13: Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS César Serrano et al., Barcelona, Spain

Other 15/07/2020

News about HIPEC in colorectal cancer

Prof. Dr. I.H.J.T. (Ignace) de Hingh presents the most important news about HIPEC in colorectal cancer such as   selection criteria for cytoreductive surgery and HIPEC for CRC - absolute and relative indications Prodige 7 study - does the study change clinical practice and if so, how? repeated cytoreductive surgery and HIPEC: an absolute contraindication? which systemic chemotherapy is used in combination with HIPEC?

Congress news 06/07/2020

Lower GI - Highlights WCGIC

In this presentation, Sara De Dosso, Oncology Institute of Southern Switzerland, Bellinzona covers the most important findings from the ESMO WCGIC for lower GI / colorectal cancer.   She selected the following studies and topics:   Colon cancer adjuvant   O-16: Relative Impact of T4 and N2 on the Efficacy of 3 versus 6 Months of Adjuvant CAPOX for High-Risk Stage II and Stage III Colon Cancer: ACHIEVE and ACHIEVE-2 Trials Takeharu Yamanaka et al., Yokohama, Japan   mCRC BRAF V600E mutated LBA-5: ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAFV600E–mutant metastatic colorectal cancer Axel Grothey et al., Tennessee, USA     SO-26: Clinical efficacy of combined PD-1/BRAF/MEK inhibition in BRAFV600 colorectal cancer patients Ryan B. Corcoran et al., Boston, MA, USA     mCRC Targeting genomic drivers of the disease SO-24: AMG510 (sotorasib), A Novel Small Molecule Inhibitor of KRASG12C, For Patients With Advanced Gastrointestinal Tumors: Results From the CodeBreak100 Phase 1 Trial John H. Strickler et al., North Carolina, USA     Liquid biopsies in mCRC O-21: METABEAM Study A combined analysis of concordance studies between liquid and tumour tissue biopsies for RAS mutations in colorectal cancer patients with a single metastasis site Yoshinori Kagawa et al., Hyogo, Japan   SO-34: Experience of a Personalized and Tumor-Informed Circulating Tumor DNA Assay for Minimal Residual Disease Detection in Oligometastatic Colorectal Cancer Patients Stacey A. Cohen University of Washington et al., Division of Oncology, Seattle, WA     Rectal cancer SO-37: Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer (EPOC 1504) Satoshi Yuki et al., Sapporo, Japan   return to overview  

Congress news 09/07/2020

Gastro-intestinale inférieur - Résumé du WCGIC

Dans cette présentation, Sara De Dosso, de l'Institut d'oncologie du sud de la Suisse, à Bellinzona, couvre les principales conclusions de l'ESMO WCGIC pour le cancer colorectal / gastro-intestinal inférieur.   Elle a sélectionné les études et les sujets suivants :   Adjuvant Cancer Colon O-16: Relative Impact of T4 and N2 on the Efficacy of 3 versus 6 Months of Adjuvant CAPOX for High-Risk Stage II and Stage III Colon Cancer: ACHIEVE and ACHIEVE-2 Trials Takeharu Yamanaka et al., Yokohama, Japan   mCRC BRAF V600E mutated LBA-5: ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAFV600E–mutant metastatic colorectal cancer Axel Grothey et al., Tennessee, USA     SO-26: Clinical efficacy of combined PD-1/BRAF/MEK inhibition in BRAFV600 colorectal cancer patients Ryan B. Corcoran et al., Boston, MA, USA     mCRC : cibler les facteurs génomiques de la maladie SO-24: AMG510 (sotorasib), A Novel Small Molecule Inhibitor of KRASG12C, For Patients With Advanced Gastrointestinal Tumors: Results From the CodeBreak100 Phase 1 Trial John H. Strickler et al., North Carolina, USA     Biopsies liquides en mCRC O-21: METABEAM Study A combined analysis of concordance studies between liquid and tumour tissue biopsies for RAS mutations in colorectal cancer patients with a single metastasis site Yoshinori Kagawa et al., Hyogo, Japan   SO-34: Experience of a Personalized and Tumor-Informed Circulating Tumor DNA Assay for Minimal Residual Disease Detection in Oligometastatic Colorectal Cancer Patients Stacey A. Cohen et al., Division of Oncology, Seattle, WA     Cancer du rectum SO-37: Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer (EPOC 1504) Satoshi Yuki et al., Sapporo, Japan

Congress news 06/07/2020

Highlights from WCGIC

Summaries of the most important findings from the ESMO World Congress on GI Cancer (WCGIC)   Two Swiss experts are presenting in concise wrap-up summaries the most important findings of the WCGIC. In a vivid discussion, 5 swiss and german experts evaluate the new results in terms of their clinical practice.   Lower GI & Colorectal Cancer - Sara De Dosso Upper GI - Thomas Winder Discussion Round on the Highlights from the WCGIC   Gastro-intestinal inférieur - Sara De Dosso Gastro-intestinale supérieure - Thomas Winder Débat sur les highlights du WCGIC        

Congress news 08/06/2020

Highlights from EHA25 virtual meeting

From 16 June 2020, you will find here four concise highlight summaries of the most important study results from the EHA25 virtual meeting.   You can access the presentations here:   AML, MDS, MPN - Dr. Goede   Aggressive Lymphoma – Professor Renner   CLL & Indolent Lymphoma - Prof. Rossi   Myeloma - Dr. Zander   Discussion Round on the practice-changing studies     The Swiss Experts:         Below you can download the announcement flyer.